Showing results (51-60 of 91) with videos related to
Sort By:
Pageof 10
Cancer Reports (Hoboken, N.J.)|August 9, 2024
Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid LeukemiaChiara Ronchini, Federica Gigli, Martina Fontanini, et al.International Journal of Cancer|June 13, 2022
Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomesElisabetta Todisco, Federica Gigli, Chiara Ronchini, et al.Cancer|May 14, 2011
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemiaAnna Guidetti, Carmelo Carlo-Stella, Marco Ruella, et al.American Journal of Hematology|August 14, 2013
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapyAlessandro Rambaldi, Cristina Boschini, Giuseppe Gritti, et al.Cytotherapy|November 3, 2009
Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte-colony-stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trialCorrado Tarella, Sergio Rutella, Francesca Gualandi, et al.International Journal of Radiation Oncology, Biology, Physics|March 15, 2016
Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter StudyMarco Ruella, Andrea Riccardo Filippi, Riccardo Bruna, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2008
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi surveyCorrado Tarella, Manuela Zanni, Michele Magni, et al.Hematology Reports|December 27, 2024
Venetoclax Plus Intensified Chemoimmunotherapy as a Bridge to Allogeneic Stem Cell Transplantation in Richter Syndrome: Report of Two CasesEnrico Derenzini, Alessandro Cignetti, Valentina Tabanelli, et al.Frontiers in Immunology|August 22, 2025
Pre-existing oncohematological disease in kidney transplant recipients: impact on graft survival, acute rejection, and long-term clinical outcomesAlberto Mella, Roberta Clari, Valeria Deiana, et al.Blood|January 5, 2002
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignanciesPaolo Corradini, Corrado Tarella, Attilio Olivieri, et al.Pageof 10